E
Emily E. Coates
Researcher at National Institutes of Health
Publications - 35
Citations - 2107
Emily E. Coates is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 17, co-authored 25 publications receiving 1617 citations. Previous affiliations of Emily E. Coates include University of Maryland, College Park & Imperial College London.
Papers
More filters
Journal ArticleDOI
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch,Eli Boritz,Emily E. Coates,Adam DeZure,Patrick J Madden,Pamela Costner,Mary E. Enama,Sarah H. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Ingelise J. Gordon,Joseph P. Casazza,Michelle Conan-Cibotti,Stephen A. Migueles,Randall Tressler,Robert T. Bailer,Adrian B. McDermott,Sandeep Narpala,Sijy O'Dell,Gideon Wolf,Jeffrey D. Lifson,Brandie A. Freemire,Robert J. Gorelick,Janardan P. Pandey,Sarumathi Mohan,Nicolas Chomont,Rémi Fromentin,Tae-Wook Chun,Anthony S. Fauci,Richard M. Schwartz,Richard A. Koup,Daniel C. Douek,Zonghui Hu,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood,Vrc Study Team +37 more
TL;DR: A single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains, demonstrating the virological effect of this neutralizing antibody and highlighting the need for combination strategies to maintain virus suppression.
Journal ArticleDOI
Extracellular matrix formation and mineralization on a phosphate-free porous bioactive glass scaffold using primary human osteoblast (HOB) cells.
TL;DR: The scaffolds supported osteoblast growth and induced differentiation, within the 3-week culture period, as depicted by enhanced ALPase enzymatic activity, without the addition of supplementary factors such as ascorbic acid, beta-glycerophosphate and dexamethasone.
Journal ArticleDOI
Chimpanzee Adenovirus Vector Ebola Vaccine
Julie E. Ledgerwood,Adam DeZure,Daphne A. Stanley,Emily E. Coates,Laura Novik,Mary E. Enama,Nina M. Berkowitz,Zonghui Hu,Gyan Joshi,Aurélie Ploquin,Sandra Sitar,Ingelise J. Gordon,Sarah A. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Galina Yamshchikov,François Roman,Alfredo Nicosia,Stefano Colloca,Riccardo Cortese,Robert T. Bailer,Richard M. Schwartz,Mario Roederer,John R. Mascola,Richard A. Koup,Nancy J. Sullivan,Barney S. Graham +26 more
TL;DR: In this paper, a replication-defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species, was rapidly advanced into phase 1 clinical evaluation.
Journal ArticleDOI
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Julie E. Ledgerwood,Emily E. Coates,Galina Yamshchikov,Jamie G. Saunders,LaSonji A. Holman,Mary E. Enama,Adam DeZure,Rebecca M. Lynch,Ingelise J. Gordon,Sarah A. Plummer,Cynthia S. Hendel,Amarendra Pegu,Michelle Conan-Cibotti,Sandra Sitar,Robert T. Bailer,Sandeep Narpala,Adrian B. McDermott,Mark K. Louder,Sijy O'Dell,Sankar Mohan,Janardan P. Pandey,Richard M. Schwartz,Zonghui Hu,Richard A. Koup,Edmund V. Capparelli,John R. Mascola,Barney S. Graham +26 more
TL;DR: The human monoclonal antibody VRC01 was well tolerated when delivered i.v. or s.c. and demonstrated expected half‐life and pharmacokinetics for a human immunoglobulin G.mAb, and dosing schedules for planning HIV‐1 prevention efficacy studies are informed.
Journal ArticleDOI
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Martin R. Gaudinski,Emily E. Coates,Katherine V. Houser,Grace L. Chen,Galina Yamshchikov,Jamie G. Saunders,LaSonji A. Holman,Ingelise J. Gordon,Sarah H. Plummer,Cynthia S. Hendel,Michelle Conan-Cibotti,Margarita M. Gomez Lorenzo,Sandra Sitar,Kevin Carlton,Carolyn M. Laurencot,Robert T. Bailer,Sandeep Narpala,Adrian B. McDermott,Aryan M. Namboodiri,Janardan P. Pandey,Richard M. Schwartz,Zonghui Hu,Richard A. Koup,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood +26 more
TL;DR: The human bnMAb VRC01LS was safe and well tolerated when delivered intravenously or subcutaneously and the half-life was more than 4-fold greater when compared to wild-type VRC03, designed for extended serum half- life by increased binding affinity to the neonatal Fc receptor.